25 Results for "

T cell suppression

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "T cell suppression" in MCE Product Catalog:

Cat. No.: HY-P992361

Research Areas:  

Cancer

HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 + Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .
loading...
    loading...
Cat. No.: HY-109061BR
CAS No.: 2247995-37-3
Synonyms: YH25448 mesylate (Standard); GNS-1480 mesylate (Standard)
Target:  

Reference Standards

Research Areas:  

Cancer

Lazertinib mesylate (Standard) is the analytical standard of Lazertinib (mesylate) (HY-109061B). This product is intended for research and analytical applications. Lazertinib (YH25448) mesylate is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine Kinase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib mesylate inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib mesylate can be used in the study of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-109061R
CAS No.: 1903008-80-9
Synonyms: YH25448 (Standard); GNS-1480 (Standard)
Lazertinib (Standard) is the analytical standard of Lazertinib (HY-109061). This product is intended for research and analytical applications. Lazertinib (YH25448) is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine Kinase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib can be used in the study of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-182048
Target:  

PD-1/PD-L1 mTOR

Research Areas:  

Cancer

PD-1/PD-L1-IN-62 is a PD-L1 inhibitor and mTOR modulator. PD-1/PD-L1-IN-62 inhibits PD-L1 with an IC50 of 6.9 nM and abrogates immune suppression mediated by the PD-1/PD-L1 pathway. By inhibiting mTOR phosphorylation and downregulating the downstream target SREBP1, PD-1/PD-L1-IN-62 significantly reduces cholesterol and triglyceride levels to decrease lipid accumulation. PD-1/PD-L1-IN-62 promotes the infiltration of CD3 +CD8 + T cells into tumor tissues, thereby effectively inhibiting tumor growth. PD-1/PD-L1-IN-62 can be used for the research of hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-189364
CAS No.: 88262-44-6
Synonyms: SMC247-9
Research Areas:  

Cancer

(DL)-3,5-Dimethyltyrosine (SMC247-9) is a selective APOBEC3B inhibitor optimized from SMC247, with an IC50 of 50 pM. (DL)-3,5-Dimethyltyrosine binds to the APOBEC3B protein, reduces intracellular APOBEC3B protein abundance partially through a lysosome-dependent pathway, enhances IL-15 expression in tumor cells, and relieves the suppression of CD8 + T cells by tumor cells in an IL-15-dependent manner. (DL)-3,5-Dimethyltyrosine attenuates tumor- and macrophage-derived chemokine-mediated macrophage chemotaxis and inhibits pathological myeloid inflammatory signaling. (DL)-3,5-Dimethyltyrosine inhibits tumor growth in the immune checkpoint blockade-responsive MC38 syngeneic mouse model and produces synergistic effects with anti-PD-L1 in the immune checkpoint blockade-resistant TC-1 tumor model; it also ameliorates anti-PD-1-exacerbated DSS-induced colitis-like intestinal inflammatory injury. (DL)-3,5-Dimethyltyrosine can be used in research related to tumor immunotherapy .
loading...
    loading...